Last reviewed · How we verify
ALK4290
At a glance
| Generic name | ALK4290 |
|---|---|
| Also known as | AKST4290, BI 144807 |
| Sponsor | Alkahest, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration (PHASE2)
- Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALK4290 CI brief — competitive landscape report
- ALK4290 updates RSS · CI watch RSS
- Alkahest, Inc. portfolio CI